GET A PIECE OF KEVAHEALTH
Virtual care for respiratory illnesses
$23,714.76 Raised
REASONS TO INVEST
Our technology aims to prevent ER visits for patients and reduce the physician burden through a Bluetooth-connected device for highly accurate home monitoring of symptoms along with an app that transfers valuable data to doctors and nurses.
The Remote Patient Monitoring market has experienced explosive growth since the pandemic, predicted to expand from $53.6 billion to $175.2 billion by 2027 at a CAGR of 26.7%.**
Our highly qualified team and innovative product has won a CTIA Wireless Foundation Award, and we were featured in the Babson U.S. Annual GEM Report.***
Overview
Empowering Patients with At-Home Respiratory Monitoring
Keva Health is seeking to close healthcare gaps in chronic care management by engaging patients in their own medical condition. As our founders treated their daughter’s asthma, they found many limitations in the transition from episodic monitoring in a doctor’s care, to continuous monitoring at home in between visits. We designed our Respiratory Remote Patient Monitoring Platform to provide 24/7 at-home care, improving patient quality of life while simultaneously reducing the healthcare economic burden.
The Problem & Our solution
Improving Outcomes and Lowering Costs
The costs related to acute exacerbation of COPD are estimated to be approximately $4069/year per patient, increasing the frequency and severity of symptoms (Source). Meanwhile, Asthma affects over 20 million Americans– essentially 1 in 13 people (Source). The costs of treating and monitoring these diseases are increasing, without significant advances in the quality of care.
Our Bluetooth-connected devices, user-friendly app, and physician platform track key patient vitals including lung function. Our unique patent pending engine allows us to use patients' history and published guidelines on the standard of care to provide guidance and nudges thereby improving outcomes. By providing automated guidance and escalation management we allow the physicians to focus on the patients that need the most attention. Access to data from devices and the patient's history outside of the office enables physicians to make better decisions. We charge a per-patient fee to the physician for providing the Keva Health program to their patients.
the market & Our Traction
Award-Winning Innovation in the
Fast-Growing Telehealth Space
The Remote Patient Monitoring market is quickly expanding, projected to grow from $53.6 billion to $175.2 billion by 2027, at a Compounded Annual Growth Rate (CAGR) of 26.7% (Source). This growth has increased tremendously since the Covid-19 pandemic heightened demand for telehealth options. Now, nearly 76% of hospitals in the U.S. offer some form of virtual care for their patients (Source).
*The above testimonials may not be representative of the opinions of other medical experts or the experiences of other customers and is not a guarantee of future performance or success.
*The above testimonials may not be representative of the opinions of other medical experts or the experiences of other customers and is not a guarantee of future performance or success.
Recently, we signed a major new partnership with a digital formulary platform company and presented our results at the CHEST Conference. We have earned several awards for our technology, including the Silver Award for Business Excellence, the Connect Tech Innovation Challenge Award, and a grant from Mass Tech Innovation. We were also a finalist for the CTIA Wireless Foundation Award. We currently have a patent pending, protecting our systems and methods to monitor and manager respiratory diseases using a combination of the app, our device, and our unique platform. This patent can eventually be expanded to any chronic disease.
Why Invest
Bringing Respiratory Care to All Patients
With award-winning technology and exciting new partnerships, we believe we are ready to get our product in the hands of as many patients as possible. We plan to further develop our technology, build a robust marketing and sales team to further scale up our product, and establish its presence in the chronic respiratory disease market. Join us, as we improve the quality of life for people suffering from chronic respiratory illnesses by providing quality at-home symptom monitoring to patients everywhere.
ABOUT
HEADQUARTERS
251 Little Falls Dr.
Wilmington, DE 19808
WEBSITE
View Site
Keva Health has developed a SaaS platform to provide remote monitoring of respiratory illnesses at home. Our mission is to help the tens of millions of adults and children suffering from chronic respiratory illnesses improve their quality of life with our suite of digital health products, including our patient app, Bluetooth-powered devices, physician platform, and nursing services. Our award-winning product is already in-market and we believe we are ready to scale. KevaHealth is in the revenue stage of development.
TEAM
Jyotsna Mehta
CEO & Co-Founder
Shail Mehta
Chief Technical officer & Co-founder
Shail has experience working with startups and large organizations, with the proven ability to produce revenue-generating products. He has worked with hosted and SaaS solutions to create product experiences that delight end users.
Shail works 10 hours a week on KevaHealth.
Dr. Ramin Rafie, MD
Clinical Advisor
Ramin works 1-2 hours a week on KevaHealth
Dr. Varada Divgi
Director, Pediatric Pulmonary Program
Dr. Varada Divgi works 2-4 hours a week on KevaHealth.
Gustavo Bottan
Advisor, Partnerships
Gustavo works 0.5 hours a week on KevaHealth.
Priya Anand
Director, Marketing
Dr. Philip Silkoff
Clinical Advisor
Phillip works 1 hour a week on KevaHealth.
Dr. Dhrumil Shah
Clinical Advisor
Dr. Shah works 1-2 hours a week on KevaHealth.
Dr. Paul Helmuth
Clinical Advisor
Dr. Helmuth works 1 hour a week on KevaHealth.
Vijay Bhatt
Advisor
Vijay works 1 hour a week on KevaHealth.
TERMS
KevaHealth
Overview
PRICE PER SHARE
$1.22
DEADLINE
Jun 2, 2023
VALUATION
$10M
FUNDING GOAL
$10k - $1.23M
Breakdown
MIN INVESTMENT
$448.96
MAX INVESTMENT
$1,234,999.90
MIN NUMBER OF SHARES OFFERED
8,196
MAX NUMBER OF SHARES OFFERED
1,012,295
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Investment Incentives & Bonuses*
Time-Based:
Friends and Family Early Birds
Invest within the 72 hours and receive 20% bonus shares.
Super Early Bird Bonus
Invest within the first week and receive 15% bonus shares.
Early Bird Bonus
Invest within the first three weeks and receive 10% bonus shares.
Amount-Based:
$450+
Invest $450+ and receive 2% Bonus Shares.
$1,000+
Invest $1,000 + and receive 5% Bonus Shares.
$4,500 +
Invest $4,500+ and receive 10 % Bonus Shares.
$15,000+
Invest $15,000+ and receive 15% Bonus Shares.
$20,000+
Invest $20,000+ and receive 20% Bonus Shares + Private zoom call with Chief Executive and/or Chief Technology Officer.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners’ Bonus
KevaHealth Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. Owner’s bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.22 per share, you will receive 110 Common Stock, meaning you’ll own 110 shares for $122. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments.
ALL UPDATES
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
JOIN THE DISCUSSION
0/2500
Kendall R. Pagone
7 months ago
I might have miss it, but how much does the average person/ family pay for your services per visit, month, or year?
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Adam Sampson
6 months ago
1
0